PTN might be worth watching. At the lower end of 52 week range, 1.20 -5.89 - presently 2.54, but potential to significantly move up. Picked this up while watching Discovery Channel.
Palatin Technologies, Inc. is a development-stage biopharmaceutical company primarily focused on developing melanocortin (MC)-based therapeutics. The MC family of receptors has been identified with a variety of conditions and diseases, including sexual dysfunction, obesity, anorexia, cachexia, inflammation and drug abuse. PT-141 is Palatin's lead therapeutic drug candidate, and is in clinical development for the treatment of both male and female sexual dysfunction. LeuTech is the Company's proprietary radiolabled monoclonal antibody for imaging and diagnosing infections. In addition, the Company has several preclinical drug candidates under investigation for various therapeutic indications, including sexual dysfunction, obesity, cachexia and inflammation utilizing its patented drug discovery platform.
I'd be interested in the views of others on the board. |
